Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights
This article was originally published in Scrip
Exelixis Inc. will bring in $260m in up front and milestone payments in 2016 alone under its new partnership with Ipsen for ex-US development and commercialization of Cometriq (cabozantinib), while the company awaits both US and EU approvals of the drug for a form of kidney cancer.
You may also be interested in...
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.
During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.